FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965851736> ?p ?o ?g. }

• W2965851736 endingPage "4482" @default.
• W2965851736 startingPage "4482" @default.
• W2965851736 abstract "Abstract Mcl-1 is highly expressed in a variety of human cancers (including those of hematopoietic and lymphoid origin) and is exploited by cancer cells to evade cell death and to develop resistance to diverse chemotherapeutic agents. We disclose, for the first time, the structure of S64315 (also named MIK665) a highly potent and selective inhibitor of Mcl-1 with improved potency over its predecessor S63845 (Kotschy et al, Nature, 2016). S64315/MIK665 is currently in phase 1 in AML (Acute Myeloid Leukemia) and MDS (Myelodysplastic Syndrome) (EudraCT 2016-003768-38, NCT 02979366) and in MM (Multiple Myeloma) and lymphoma (NCT02992483). A fragment-based, structure-guided drug discovery effort led to the identification of S64315/MIK665 that binds to human Mcl-1 with a sub-nanomolar affinity (Ki 0.048 nM) and selectively over other anti-apoptotic Bcl-2 family members. It has similar affinity for human, rat, dog and monkey Mcl-1 but about a ten-fold lower affinity for mouse Mcl-1. S64315/MIK665 causes dose-dependent activation of the intrinsic apoptosis pathway in a Bax/Bak-dependent manner, as measured by increased caspase activity and cleaved PARP. S64315/MIK665 shows strong cell killing activity in a diverse panel of human hematological tumor cell lines, including AML, lymphoma and MM. The activity profile of S64315/MIK665 is distinct from that of venetoclax, a selective Bcl2 inhibitor. In vivo, S64315 as single agent demonstrated potent and dose-dependent apoptotic and antitumor response after intravenous administration in several human hematological tumor models grafted in immuno-compromised mice and rats. Complete regression of established tumors, at well tolerated doses, was achieved using different intravenous dosing regimens in rats as well as in mice. Finally, dual BH3-mimetic targeting approach combining S64315/MIK665 with BCL2 inhibitors showed strong and durable antitumor responses in several hematological tumor models both in vitro and in vivo. Citation Format: Ana Leticia Maragno, Prakash Mistry, András Kotschy, Zoltán Szlavik, James Murray, James Davidson, Gaëtane Le Toumelin-Braizat, Maïa Chanrion, Alain Bruno, Audrey Claperon, Heiko Maacke, Erick Morris, Youzhen Wang, Alix Derreal, Márton Csekei, Attila Paczal, Zoltán Szabo, Szabolcs Sipos, Agnes Proszenyak, Balázs Balint, Allan Surgenor, Pawel Dokurno, Natalia Matassova, Ijen Chen, Gaëlle Lysiak-Auvity, Anne-Marie Girard, Fabienne Grave, Frédéric Colland, Ensar Halilovic, Olivier Geneste. S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4482." @default.
• W2965851736 created "2019-08-13" @default.
• W2965851736 creator A5002797759 @default.
• W2965851736 creator A5002902099 @default.
• W2965851736 creator A5003494614 @default.
• W2965851736 creator A5005231854 @default.
• W2965851736 creator A5006047218 @default.
• W2965851736 creator A5010727651 @default.
• W2965851736 creator A5010729017 @default.
• W2965851736 creator A5010914815 @default.
• W2965851736 creator A5015145109 @default.
• W2965851736 creator A5019757608 @default.
• W2965851736 creator A5020512155 @default.
• W2965851736 creator A5025363975 @default.
• W2965851736 creator A5029798223 @default.
• W2965851736 creator A5029966483 @default.
• W2965851736 creator A5031130811 @default.
• W2965851736 creator A5044251543 @default.
• W2965851736 creator A5047563992 @default.
• W2965851736 creator A5049488273 @default.
• W2965851736 creator A5050805316 @default.
• W2965851736 creator A5051136232 @default.
• W2965851736 creator A5058267528 @default.
• W2965851736 creator A5063661309 @default.
• W2965851736 creator A5072179479 @default.
• W2965851736 creator A5072358528 @default.
• W2965851736 creator A5077311966 @default.
• W2965851736 creator A5081262355 @default.
• W2965851736 creator A5085794984 @default.
• W2965851736 creator A5087984939 @default.
• W2965851736 creator A5089513681 @default.
• W2965851736 creator A5091900712 @default.
• W2965851736 date "2019-07-01" @default.
• W2965851736 modified "2023-10-18" @default.
• W2965851736 title "Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models" @default.
• W2965851736 doi "https://doi.org/10.1158/1538-7445.am2019-4482" @default.
• W2965851736 hasPublicationYear "2019" @default.
• W2965851736 type Work @default.
• W2965851736 sameAs 2965851736 @default.
• W2965851736 citedByCount "7" @default.
• W2965851736 countsByYear W29658517362020 @default.
• W2965851736 countsByYear W29658517362021 @default.
• W2965851736 countsByYear W29658517362022 @default.
• W2965851736 countsByYear W29658517362023 @default.
• W2965851736 crossrefType "journal-article" @default.
• W2965851736 hasAuthorship W2965851736A5002797759 @default.
• W2965851736 hasAuthorship W2965851736A5002902099 @default.
• W2965851736 hasAuthorship W2965851736A5003494614 @default.
• W2965851736 hasAuthorship W2965851736A5005231854 @default.
• W2965851736 hasAuthorship W2965851736A5006047218 @default.
• W2965851736 hasAuthorship W2965851736A5010727651 @default.
• W2965851736 hasAuthorship W2965851736A5010729017 @default.
• W2965851736 hasAuthorship W2965851736A5010914815 @default.
• W2965851736 hasAuthorship W2965851736A5015145109 @default.
• W2965851736 hasAuthorship W2965851736A5019757608 @default.
• W2965851736 hasAuthorship W2965851736A5020512155 @default.
• W2965851736 hasAuthorship W2965851736A5025363975 @default.
• W2965851736 hasAuthorship W2965851736A5029798223 @default.
• W2965851736 hasAuthorship W2965851736A5029966483 @default.
• W2965851736 hasAuthorship W2965851736A5031130811 @default.
• W2965851736 hasAuthorship W2965851736A5044251543 @default.
• W2965851736 hasAuthorship W2965851736A5047563992 @default.
• W2965851736 hasAuthorship W2965851736A5049488273 @default.
• W2965851736 hasAuthorship W2965851736A5050805316 @default.
• W2965851736 hasAuthorship W2965851736A5051136232 @default.
• W2965851736 hasAuthorship W2965851736A5058267528 @default.
• W2965851736 hasAuthorship W2965851736A5063661309 @default.
• W2965851736 hasAuthorship W2965851736A5072179479 @default.
• W2965851736 hasAuthorship W2965851736A5072358528 @default.
• W2965851736 hasAuthorship W2965851736A5077311966 @default.
• W2965851736 hasAuthorship W2965851736A5081262355 @default.
• W2965851736 hasAuthorship W2965851736A5085794984 @default.
• W2965851736 hasAuthorship W2965851736A5087984939 @default.
• W2965851736 hasAuthorship W2965851736A5089513681 @default.
• W2965851736 hasAuthorship W2965851736A5091900712 @default.
• W2965851736 hasConcept C104317684 @default.
• W2965851736 hasConcept C121608353 @default.
• W2965851736 hasConcept C126322002 @default.
• W2965851736 hasConcept C127561419 @default.
• W2965851736 hasConcept C150903083 @default.
• W2965851736 hasConcept C190283241 @default.
• W2965851736 hasConcept C203014093 @default.
• W2965851736 hasConcept C207001950 @default.
• W2965851736 hasConcept C2776364478 @default.
• W2965851736 hasConcept C2777938653 @default.
• W2965851736 hasConcept C2778461978 @default.
• W2965851736 hasConcept C2779176958 @default.
• W2965851736 hasConcept C2779282312 @default.
• W2965851736 hasConcept C2779338263 @default.
• W2965851736 hasConcept C2779675984 @default.
• W2965851736 hasConcept C502942594 @default.
• W2965851736 hasConcept C55493867 @default.
• W2965851736 hasConcept C71924100 @default.
• W2965851736 hasConcept C86803240 @default.
• W2965851736 hasConcept C98274493 @default.
• W2965851736 hasConceptScore W2965851736C104317684 @default.
• W2965851736 hasConceptScore W2965851736C121608353 @default.
• W2965851736 hasConceptScore W2965851736C126322002 @default.

• next